NewsRamp™’s Post

#CRDL Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study! The MAvERIC Phase II study in Recurrent Pericarditis is now completed, with Results to be Presented at the American Heart Association Scientific Sessions 2024. Cardiol Therapeutics Inc. a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced the data from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis will be reported in an oral presentation as part of the Laennec Clinician-Educator Award & Lecture that runs from 9:45 a.m. to 11:00 a.m. Central Time, on Monday, November 18th, 2024, at the American Heart Association. Having recently reported the positive primary endpoint data from the MAvERIC-Pilot study demonstrating that oral administration of our small molecule CardiolRx™ led to marked reductions in pericarditis pain and inflammation at 8 weeks, we are delighted that the data has been accepted for oral presentation in such a prestigious session of the American Heart Association Scientific Sessions 2024, the premier global event for advancements in cardiovascular science and medicine," said David Elsley, Cardiol Therapeutics' President and Chief Executive Officer. Read the full article here https://lnkd.in/gbnnyYcX Cardiol Therapeutics Inc. #PFE #MRNA #BIOTECH #PHARMA

Sirius begins patient dosing in phase 1 trial of next─generation, long─acting factor XI siRNA anticoagulant to treat thromboembolic disorders

🚀 Exciting News from Kyverna Therapeutics! 🌟 #FDA #FastTrack #InnovationInHealthcare #MultipleSclerosisTherapy #KyvernaTherapeutics 🔬 The FDA has just granted fast track designation to Kyverna Therapeutics' groundbreaking CAR T-cell therapy, KYV-101, specifically aimed at treating multiple sclerosis (MS). This is a major leap forward in autoimmune disease treatment, showcasing Kyverna's commitment to innovative healthcare solutions. 👩🔬KYV-101, an autologous, fully human CD19 chimeric antigen receptor (CAR) T-cell therapy, is designed to target the CD19 protein on the B cell surface - a key player in various autoimmune diseases. This therapy represents a novel approach, modifying patients' T cells to effectively identify and eliminate B cells. 🧬 Originating from a collaborative effort with the US National Institutes of Health, the CAR in KYV-101 has been engineered for enhanced tolerability and has already shown promise in a 20-subject Phase I oncology trial. 🔎 Following the FDA's fast track designation for KYV-101 in myasthenia gravis last month, this new status for MS treatment accelerates the development and review process, addressing a critical unmet medical need. 🌍 As a clinical-stage biopharmaceutical leader, Kyverna is not stopping here. Plans are underway for further trials of KYV-101 in systemic sclerosis, myasthenia gravis, and multiple sclerosis, reinforcing their dedication to transforming the treatment landscape for autoimmune diseases. 💡 Kyverna CEO Peter Maag remarks, “This marks another important milestone in our endeavor to change the treatment paradigm with KYV-101.” 🔗 Join us in celebrating this significant advancement in healthcare and stay tuned for more updates on Kyverna’s journey in revolutionizing autoimmune disease treatment! #HealthcareInnovation #CARTherapy #AutoimmuneDisease #ClinicalTrials #Biopharmaceuticals #KyvernaUpdate #HealthTech #MedicalAdvancement

InCarda Therapeutics showcases promising results with FlecIH-103, an inhaled solution for converting paroxysmal atrial fibrillation (PAF) to sinus rhythm. The Phase 3 RESTORE-1 trial demonstrated a 31% cardioversion rate with inhaled flecainide, achieving normal sinus rhythm in approximately 13 minutes, significantly outperforming the placebo. Despite low enrollment, the study highlighted substantial pharmacoeconomic benefits, with patients experiencing quicker discharge and symptom resolution post-conversion. Notably, the need for electrical cardioversion decreased in the treatment arm, showcasing the efficacy of FlecIH-103. InCarda is now shifting towards a new drug-delivery platform backed by promising Phase 1 clinical data. These positive results support the continuation of the study, potentially propelling FlecIH-103 into registrational trials. The findings from the RESTORE-1 trial underscore the safety and effectiveness of inhaled flecainide as a rapid and non-invasive therapy for PAF patients, reducing the reliance on invasive procedures. Explore more: https://lnkd.in/dGwkjpmb Meisa Propst Prashanti Madhavapeddi - PhD

Announcement made for new potential treatment results for Pericarditis, a Inflammatory Heart Disease Cardiol Therapeutics, Inc., is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Cardiol Therapeutics, Inc. has clinical studies in progress for the potential treatment of Recurrent Pericarditis (MAvERIC Study) and Acute Myocarditis (Archer Trial), as well as developing a drug formulation intended for use in Heart Failure. Heart Failure is a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding $30 billion annually. Please read the full article which documents marked reductions in pericarditis pain and inflammation with the administration of CardiolRx. https://lnkd.in/ggGuzmrV

Enterprise Therapeutics has dosed the first patient in its pivotal Phase IIa clinical trial, which is investigating the efficacy and safety of ETD001 — an epithelial sodium channel (#ENaC) inhibitor designed to enhance hydration and mucus clearance in patients with cystic fibrosis. The study is also focusing on the suitability of such a treatment for the 10% of cystic fibrosis patients who are ineligible for CFTR modulators. #cysticfibrosis #clinicaltrials #CFTRmodulators #ENaCinhibitors https://lnkd.in/env3Jv_N

Cardiol Therapeutics (CRDL | NSDQ) Announces Completion of the MAvERIC Phase II Study! The MAvERIC Phase II study in Recurrent Pericarditis is now completed, with Results to be Presented at the American Heart Association Scientific Sessions 2024. Cardiol Therapeutics Inc. a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced the data from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis will be reported in an oral presentation as part of the Laennec Clinician-Educator Award & Lecture that runs from 9:45 a.m. to 11:00 a.m. Central Time, on Monday, November 18th, 2024, at the American Heart Association. Having recently reported the positive primary endpoint data from the MAvERIC-Pilot study demonstrating that oral administration of our small molecule CardiolRx™ led to marked reductions in pericarditis pain and inflammation at 8 weeks, we are delighted that the data has been accepted for oral presentation in such a prestigious session of the American Heart Association Scientific Sessions 2024, the premier global event for advancements in cardiovascular science and medicine," said David Elsley, Cardiol Therapeutics' President and Chief Executive Officer. Read the full article here… https://lnkd.in/gbnnyYcX #CRDL #CARDIOL #BIOTECH #PHARMA #TRIALS #Pericarditis Cardiol Therapeutics Inc.

Another day, another life-changing scientific break through. Parkinson's particularly hits a raw nerve. Anyone who's seen a senior citizen suffering from this terrible affliction has got to feel some joy today. The bizarre paradox of America: The world's best medical innovation ecosystem coupled with the world's worst care delivery system. And "system" is being generous. The better word is probably "situation." #Biotech #Biotechnology #Bigpharma #Pharmaceutical #Parkinsons #Neurology

Hemab Therapeutics Presents Positive Phase 1 Results for HMB-001 in Glanzmann Thrombasthenia at 2024 EAHAD Annual Congress "The first clinical data for HMB-001 in Glanzmann suggest that the demonstrated mechanism is suitable as a new prophylactic treatment for people with neglected blood clotting disorders who face severe, potentially life-threatening bleeds every day," said Joe Vogel, Senior Director and Program Lead for HMB-001 at Hemab. "With Phase 2 already underway, we are committed to advancing clinical evaluation of HMB-001 toward bringing life-changing preventative treatments to improve patients' quality of life." VINODKUMAR VORA Nimish Dudhatra https://lnkd.in/d8dfjXwh

Exciting developments in NASH treatment! Stephen Harrison, MD, delves into groundbreaking Phase 3 data on Resmetirom, offering hope for NASH resolution and fibrosis improvement. The results from the MAESTRO-NASH trial, published in NEJM, underscore Resmetirom's potential to revolutionize NASH management. With the March 14 PDUFA date looming, backed by Madrigal Pharmaceuticals, these findings could mark a historic milestone in addressing the urgent unmet need in liver disease therapeutics. Stay tuned for the full interview and analysis! #NASH #LiverHealth #MedicalAdvancements #MadrigalPharma #HCPLive